OXFORD, Mass., April 17, 2018 -- IPG Photonics Corporation (NASDAQ:IPGP) will release its first quarter 2018 financial results before the market opens on Tuesday, May 1, 2018. The company will hold a conference call to review these results at 10:00 am EDT that same day. To access the call, please dial 877-407-6184 in the United States or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the company’s website at investor.ipgphotonics.com.
About IPG Photonics Corporation
IPG Photonics Corporation is the leader in high-power fiber lasers and amplifiers used primarily in materials processing and other diverse applications. The company’s mission is to make its fiber laser technology the tool of choice in mass production. IPG accomplishes this mission by delivering superior performance, reliability and usability at a lower total cost of ownership compared with other types of lasers and non-laser tools, allowing end users to increase productivity and decrease costs. A member of the S&P 500® Index, IPG is headquartered in Oxford, Massachusetts and has more than 25 facilities worldwide. For more information, visit www.ipgphotonics.com.
Contact
James Hillier
Vice President of Investor Relations
IPG Photonics Corporation
508-373-1467
[email protected]


Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Toyota Global Sales Fall as China Demand Slumps
Mercer International Stock Surges 45% on C$20 Million Canada Funding
Amazon Secures 200 MW Wind Power Deals in Sweden
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Google Changes EU Spam Policy Amid Antitrust Scrutiny
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 



